Information Provided By:
Fly News Breaks for December 23, 2019
Dec 23, 2019 | 10:24 EDT
Stifel analyst Paul Matteis believes the FDA approval of Intra-Cellular's (ITCI) Lumateperone reaffirms that the agency is more flexible than average for neuroscience drugs, again setting precedent that the agency will often look at a mixed efficacy package in CNS through a "glass half full lens." While the details for each "are unique," the analyst believes the news are incrementally positive for Sage Therapeutics (SAGE), Acadia Pharmaceuticals (ACAD) and Karuna Therapeutics (KRTX) and to an extent Biogen (BIIB).